[1] |
KARLSEN TH, FOLSERAAS T, THORBURN D, et al. Primary sclerosing cholangitis - a comprehensive review[J]. J Hepatol, 2017, 67(6): 1298-1323. DOI: 10.1016/j.jhep.2017.07.022.
|
[2] |
VESTERHUS M, KARLSEN TH. Emerging therapies in primary sclerosing cholangitis: pathophysiological basis and clinical opportunities[J]. J Gastroenterol, 2020, 55(6): 588-614. DOI: 10.1007/s00535-020-01681-z.
|
[3] |
HENSON JB, HELZBERG JH, MUIR AJ. Patient-predicted outcomes are associated with quality of life in patients with primary sclerosing cholangitis[J]. Dig Dis Sci, 2022, 67(12): 5483-5492. DOI: 10.1007/s10620-022-07482-z.
|
[4] |
de KRIJGER M, CARVALHO B, RAUSCH C, et al. Genetic profiling of colorectal carcinomas of patients with primary sclerosing cholangitis and inflammatory bowel disease[J]. Inflamm Bowel Dis, 2022, 28(9): 1309-1320. DOI: 10.1093/ibd/izac087.
|
[5] |
ABBAS N, QURAISHI MN, TRIVEDI P. Emerging drugs for the treatment of primary sclerosing cholangitis[J]. Curr Opin Pharmacol, 2022, 62: 23-35. DOI: 10.1016/j.coph.2021.11.003.
|
[6] |
NASSER-GHODSI N, MARA K, WATT KD. De novo colorectal and pancreatic cancer in liver-transplant recipients: identifying the higher-risk populations[J]. Hepatology, 2021, 74(2): 1003-1013. DOI: 10.1002/hep.31731.
|
[7] |
SINGH S, EDAKKANAMBETH VARAYIL J, LOFTUS EV Jr, et al. Incidence of colorectal cancer after liver transplantation for primary sclerosing cholangitis: a systematic review and meta-analysis[J]. Liver Transpl, 2013, 19(12): 1361-1369. DOI: 10.1002/lt.23741.
|
[8] |
BRADEN B, HALLIDAY J, ARYASINGHA S, et al. Risk for colorectal neoplasia in patients with colonic Crohn's disease and concomitant primary sclerosing cholangitis[J]. Clin Gastroenterol Hepatol, 2012, 10(3): 303-308. DOI: 10.1016/j.cgh.2011.10.020.
|
[9] |
XIE Y, CHEN X, DENG M, et al. Causal linkage between inflammatory bowel disease and primary sclerosing cholangitis: a two-sample mendelian randomization analysis[J]. Front Genet, 2021, 12: 649376. DOI: 10.3389/fgene.2021.649376.
|
[10] |
LUNDBERG BÅVE A, BERGQUIST A, BOTTAI M, et al. Increased risk of cancer in patients with primary sclerosing cholangitis[J]. Hepatol Int, 2021, 15(5): 1174-1182. DOI: 10.1007/s12072-021-10214-6.
|
[11] |
FUNG BM, LINDOR KD, TABIBIAN JH. Cancer risk in primary sclerosing cholangitis: Epidemiology, prevention, and surveillance strategies[J]. World J Gastroenterol, 2019, 25(6): 659-671. DOI: 10.3748/wjg.v25.i6.659.
|
[12] |
ROMPIANESI G, RAVIKUMAR R, JOSE S, et al. Incidence and outcome of colorectal cancer in liver transplant recipients: A national, multicentre analysis on 8115 patients[J]. Liver Int, 2019, 39(2): 353-360. DOI: 10.1111/liv.13947.
|
[13] |
KOMAKI Y, KOMAKI F, MICIC D, et al. Risk of colorectal cancer in chronic liver diseases: a systematic review and meta-analysis[J]. Gastrointest Endosc, 2017, 86(1): 93-104.e5. DOI: 10.1016/j.gie.2016.12.009.
|
[14] |
GOSSARD AA, GORES GJ. Primary sclerosing cholangitis: what the gastroenterologist and hepatologist needs to know[J]. Clin Liver Dis, 2017, 21(4): 725-737. DOI: 10.1016/j.cld.2017.06.004.
|
[15] |
SHAH SC, TEN HOVE JR, CASTANEDA D, et al. High risk of advanced colorectal neoplasia in patients with primary sclerosing cholangitis associated with inflammatory bowel disease[J]. Clin Gastroenterol Hepatol, 2018, 16(7): 1106-1113.e3. DOI: 10.1016/j.cgh.2018.01.023.
|
[16] |
HORSLEY-SILVA JL, RODRIGUEZ EA, FRANCO DL, et al. An update on cancer risk and surveillance in primary sclerosing cholangitis[J]. Liver Int, 2017, 37(8): 1103-1109. DOI: 10.1111/liv.13354.
|
[17] |
TRIVEDI PJ, CROTHERS H, MYTTON J, et al. Effects of primary sclerosing cholangitis on risks of cancer and death in people with inflammatory bowel disease, based on sex, race, and age[J]. Gastroenterology, 2020, 159(3): 915-928. DOI: 10.1053/j.gastro.2020.05.049.
|
[18] |
LOFTUS EV, SANDBORN WJ, TREMAINE WJ, et al. Risk of colorectal neoplasia in patients with primary sclerosing cholangitis[J]. Gastroenterology, 1996, 110(2): 432-440. DOI: 10.1053/gast.1996.v110.pm8566590.
|
[19] |
ADAMOWICZ M, STUKAN I, MILKIEWICZ P, et al. Modulation of mismatch repair and the SOCS1/p53 axis by microRNA-155 in the colon of patients with primary sclerosing cholangitis[J]. Int J Mol Sci, 2022, 23(9): 4905. DOI: 10.3390/ijms23094905.
|
[20] |
VESTERHUS M, KARLSEN TH. Emerging therapies in primary sclerosing cholangitis: pathophysiological basis and clinical opportunities[J]. J Gastroenterol, 2020, 55(6): 588-614. DOI: 10.1007/s00535-020-01681-z.
|
[21] |
SAFFIOTI F, GURUSAMY KS, HAWKINS N, et al. Pharmacological interventions for primary sclerosing cholangitis: an attempted network meta-analysis[J]. Cochrane Database Syst Rev, 2017, 3(3): CD011343. DOI: 10.1002/14651858.CD011343.pub2.
|
[22] |
JI SG, JURAN BD, MUCHA S, et al. Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease[J]. Nat Genet, 2017, 49(2): 269-273. DOI: 10.1038/ng.3745.
|